Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 8.35 USD -0.71% Market Closed
Market Cap: 1.4B USD

Wall Street
Price Targets

RLAY Price Targets Summary
Relay Therapeutics Inc

Wall Street analysts forecast RLAY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RLAY is 14.89 USD with a low forecast of 12.12 USD and a high forecast of 19.95 USD.

Lowest
Price Target
12.12 USD
45% Upside
Average
Price Target
14.89 USD
78% Upside
Highest
Price Target
19.95 USD
139% Upside
Relay Therapeutics Inc Competitors:
Price Targets
MDGL
Madrigal Pharmaceuticals Inc
5% Upside
SYNACT
SynAct Pharma AB
17% Upside
068270
Celltrion Inc
23% Upside
MRNA
Moderna Inc
24% Upside
BIOCON
Biocon Ltd
14% Upside
ALT
Altimmune Inc
421% Upside
206650
EuBiologics Co Ltd
71% Upside
HALO
Halozyme Therapeutics Inc
15% Upside

Revenue
Forecast

Revenue Estimate
Relay Therapeutics Inc

The compound annual growth rate of Relay Therapeutics Inc's revenue for the next 4 years is -2%.

N/A
Past Growth
-2%
Estimated Growth
Estimates Accuracy
-37%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Relay Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Relay Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RLAY's stock price target?
Price Target
14.89 USD

According to Wall Street analysts, the average 1-year price target for RLAY is 14.89 USD with a low forecast of 12.12 USD and a high forecast of 19.95 USD.

What is Relay Therapeutics Inc's Revenue forecast?
Projected CAGR
-2%

The compound annual growth rate of Relay Therapeutics Inc's revenue for the next 4 years is -2%.

Back to Top